homepage-top-section

Mogrify has developed a suite of platform technologies that use a systematic big-data approach for direct cellular reprogramming and to maintain cell identity. Its epiMOGRIFY and MOGRIFY platforms

The intent to acquire Libtayo was announced on 2 June this year. The two companies entered into an immuno-oncology license and collaboration agreement in 2015. As per the terms of

As part of the collaboration, the companies will carry out an observational study in chronic metabolic disease patients as well as those with increased risk of complications like

An investigational T-cell redirecting bispecific antibody, Talquetamab targets GPRC5D, a new multiple myeloma cells target, and CD3, a component of the T-cell receptor. The bispecific antibody is indicated

The regulator has approved the therapy as a potential new standard of care to treat Pompe disease, a rare, progressive and severe muscle disorder. Individuals with this disease

A fully human biologic, Cosentyx has been developed to directly inhibit interleukin-17A (IL-17A), a cytokine. The regulatory approval is granted for the use of the therapy, either alone

The combination therapy is indicated to treat unresectable or metastatic solid tumours with the BRAF V600E mutation in adult and paediatric patients aged six years and above whose

Imcivree is a melanocortin-4 receptor (MC4R) agonist which is indicated for chronic weight management in adult and paediatric patients aged six years and above with monogenic or syndromic

Atogepant is an oral calcitonin gene-related peptide [CGRP] receptor antagonist (gepant) which has been specifically developed as the preventive migraine treatment. In September last year, the drug received